← Eichor
Condition: High Grade Serous Ovarian Cancer Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: High Grade Serous Ovarian Cancer

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian Cancer
Phase 1 · 27 location(s) · National Cancer Institute (NCI) · NCT04633239Chemotherapy Combined With Propranolol Hydrochloride as Neoadjuvant Therapy for Advanced High-grade Serous Ovarian Cance
Phase 2 · 1 location(s) · Bai-Rong Xia · NCT07125391Trial of THEO-260 (Administered Via Intraperitoneal Route) in Ovarian Cancer Patients
Phase 1 · 1 location(s) · Theolytics Limited · NCT07211659MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer (MATAO)
Phase 3 · 53 location(s) · Swiss GO Trial Group · NCT04111978This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Tor
Phase 1 · 3 location(s) · Zumutor Biologics Inc. · NCT06451497Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Beva
Phase 3 · 32 location(s) · Genelux Corporation · NCT05281471Early Diagnosis of High-grade Serous Epithelial Ovarian Cancer Through the Analysis of DNA Derived From Pap Test Smear.
NA · 1 location(s) · Fondazione Policlinico Universitario Agostino Gemelli IRCCS · NCT07556562A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003)
Phase 1/Phase 2 · 29 location(s) · Merck Sharp & Dohme LLC · NCT06843447Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16)
Phase 1/Phase 2 · 1 location(s) · Beijing Biotech · NCT07480954Study of CryptiVax-1001 in Maintenance Setting for Advanced Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Phase 1 · 10 location(s) · Epitopea Ltd · NCT07665515Multi-layer Data to Improve Diagnosis, Predict Therapy Resistance and Suggest Targeted Therapies in HGSOC
NA · 1 location(s) · Turku University Hospital · NCT04846933A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
Phase 1/Phase 2 · 14 location(s) · Volastra Therapeutics, Inc. · NCT05902988Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Phase 1/Phase 2 · 66 location(s) · Genmab · NCT05579366First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, in Patients With Advanced or Metastatic Solid Tumors, Incl
Phase 1 · 6 location(s) · Accent Therapeutics · NCT06799065Modi-1 Moditope in Breast, Head and Neck, Ovarian, or Renal Cancer
Phase 1/Phase 2 · 16 location(s) · Scancell Ltd · NCT05329532A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary
Phase 2 · 92 location(s) · K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis P · NCT05128825Adaptive ChemoTherapy for Ovarian Cancer in Patients With Replased Platinum-sensitive High Grade Serous or High Grade En
Phase 2 · 1 location(s) · University College, London · NCT05080556A Study of Radspherin® in Patients With Primary Advanced Epithelial Cancer, With Peritoneal Metastasis That Are Homologo
Phase 2 · 10 location(s) · Oncoinvent Solutions AS · NCT06504147A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Phase 1 · 158 location(s) · Seagen, a wholly owned subsidiary of Pfizer · NCT04389632Role of RPL8 Protein Alterations in High-grade Serous Ovarian Carcinoma
Phase N/A · 1 location(s) · IRCCS Azienda Ospedaliero-Universitaria di Bologna · NCT06777082A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Com
Phase 1/Phase 2 · 14 location(s) · AstraZeneca · NCT06188520IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors
Phase 1 · 1 location(s) · M.D. Anderson Cancer Center · NCT05039801Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
Phase 3 · 676 location(s) · NRG Oncology · NCT06580314Developing a Test of Uterine Lavage for the Detection of Ovarian Cancer
Phase N/A · 6 location(s) · Massachusetts General Hospital · NCT04794322Investigating Idetrexed and Olaparib in Patients With Ovarian Cancer
Phase 1 · 3 location(s) · Institute of Cancer Research, United Kingdom · NCT06976892Unravelling Tumour Biology In Ovarian Cancer With Precision Imaging
NA · 1 location(s) · Institut du Cancer de Montpellier - Val d'Aurelle · NCT06084195A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
Phase 1/Phase 2 · 13 location(s) · AstraZeneca · NCT07115043CtDNA as a Novel Biomarker of Treatment Efficacy in Patients With Ovarian Cancer
Phase N/A · 1 location(s) · Xinhua Hospital, Shanghai Jiao Tong University School of Med · NCT05027828Study Looking at Biomarkers in Ovarian Cancer
NA · 7 location(s) · University Health Network, Toronto · NCT03419689Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer
Phase 2 · 6 location(s) · Canadian Cancer Trials Group · NCT04918186
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.